From MarketBeat:

1. Insider trading and analysts have recently had a high impact on Castle Biosciences, Inc. (NASDAQ:CSTL) with new price target ratings set by Guggenheim. There has also been a large decrease in short interest. Analysts believe that Castle Biosciences is doing well on the market, but they have not ranked it among the top five stocks to buy now.

2. Institutional trading of Castle Biosciences experienced quite a change recently with new stakes being made by BluePath Capital Management LLC and other hedge funds along with increased stakes made by Royal Bank of Canada and others. Currently, institutional investors own 85.75% of the company’s stock.

3. The latest figures show that Castle Biosciences, Inc. is currently trading at $21.58, with a market capitalization of $580.72 million. The company recently announced its quarterly earnings data, reporting a negative net margin of 39.32% and a negative return on equity of 19.50%. Equities analysts expect Castle Biosciences to post -2.87 EPS for the current year.

4. Castle Biosciences, Inc. aims to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product, DecisionDx-Melanoma, is a multi-gene expression profile (GEP) test designed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company’s recent performance has been carefully evaluated by top analysts who believe other stocks are better buys at this time.



Read more: Castle Biosciences, Inc. (NASDAQ:CSTL) Sees Significant Decline in Short Interest